CAMP4 Therapeutics Corp
Research CAMP4 Therapeutics Corp (CAMP) on Bullrun: market cap USD 231.08M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCAMP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 231.08M
- Financial periodQ1 2026
- RevenueUSD 3.93M
- Net income-USD 86.30M
- Free cash flow-USD 26.25M
Valuation Snapshot
latest market cap is USD 231.08M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.50M | -USD 80.40M | -USD 29.83M | n/a | -2.65 | USD 109.52M | USD 1.97M | USD 47.70M |
| FY2024 | USD 652.00K | -USD 51.79M | -USD 46.00M | n/a | -11.04 | USD 64.04M | USD 8.49M | USD 63.14M |
| FY2023 | USD 350.00K | -USD 49.29M | -USD 44.83M | 27062.0% | -124.8 | USD 38.38M | USD 241.91M | -USD 123.73M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 231.08M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 318.16M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 105.24M | n/a | n/a | n/a |
About CAMP4 Therapeutics Corp
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CAMP4 Therapeutics Corp's market cap?
CAMP4 Therapeutics Corp's market capitalization is USD 231.08M.
What does CAMP4 Therapeutics Corp do?
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.